Production of recombinant DNA fragmentation factor 40 in fusion to an antimicrobial peptide from spider venom and evaluation of its cytotoxic effects

Zahra Shafiee-Ardestani, Fatemeh Shafiee

Abstract


Background and purpose: DNA fragmentation factor 40 (DFF40) as an apoptotic molecule can represent a novel approach to cancer treatment. Lycosin-I (LYC-I), a peptide derived from spider venom, was considered for the targeted delivery of DFF40 to cancer cells. This study attempted to produce soluble DFF40-LYC-I and evaluate its selective lethal effects on HeLa cells.

Experimental approach: pTWIN1 vector was used to produce LYC-I and DFF40-LYC-I in E. coli BL21 (DE3) fused to inteins 1 and 2. IPTG concentration and incubation temperature were optimized to achieve the highest level of soluble product. To remove inteins 1 and 2 from the recombinant peptide or protein, pH shift and dithiothreitol were used for a 24-h incubation period at room temperature, respectively. MTT assay was performed to assess the biological effects of these bio-molecules on HeLa and HUVEC cell lines.

Findings/Results: LYC-I and DFF40-LYC-I were detected in SDS-PAGE with bands of approximately 57 and 97 kDa, respectively. Furthermore, the 3 and 43 kDa bands showed the purified molecules. The IC50 value of DFF40-LYC-I and DFF40 was determined as 6.6 and 17.03 µg/mL for HeLa, respectively. LYC-I had no cytotoxic effects on both cell lines, even at high concentrations.

Conclusion and implications: A new fusion protein with targeted cancer treatment potential was produced for the first time by LYC-I with a safe profile on normal cells. This fusion protein exhibited higher cytotoxic effects in cancer cells compared to normal cells. However, additional investigations are required to determine the apoptosis induction and evaluate selective toxicity against other cancer and normal cell lines.


Keywords


DFF40; DFF40-LYC-I; Lycosin-I; Targeted therapy.

Full Text:

PDF

References


Horvath L, Boyer M, Clarke S, Beale P, Beith J, Underhill C, et al. Carboplatin and vinorelbine in untreated locally advanced and metastatic non-small cell lung cancer. Lung Can. 2001;32(2):173-178. DOI: 10.1016/S0169-5002(00)00218-X.

Naumov GN, Townson JL, MacDonald IC, Wilson SM, Bramwell VHC, Groom AC, et al. Ineffectiveness of doxorubicin treatment on solitary dormant mammary carcinoma cells or late-developing metastases. Breast Cancer Res Treat. 2003;82(3):199-206.DOI: 10.1023/B:BREA.0000004377.12288.3c.

Gatti L, Zunino F. Overview of tumor cell chemoresistance mechanisms. In: Blumenthal RD, editor. Chemosensitivity: Volume II: in vivo models, imaging, and molecular regulators. 1st ed. Totowa, New Jersey: Humana; 2005.pp. 127-148.DOI:10.1385/1592598897.

Widlak P. The DFF40/CAD endonuclease and its role in apoptosis. Acta Biochim Pol. 2000;47(4):1037-1044. DOI: 10.18388/abp.2000_3957.

Gu J, Dong RP, Zhang C, McLaughlin DF, Wu MX, Schlossman SF. Functional interaction of DFF35 and DFF45 with caspase-activated DNA fragmentation nuclease DFF40. J Biol Chem. 1999;274(30):20759-20762. DOI: 10.1074/jbc.274.30.20759.

Sánchez-Osuna M, Martínez-Escardó L, Granados-Colomina C, Martínez-Soler F, Pascual-Guiral S, Iglesias-Guimarais V, et al. An intrinsic DFF40/CAD endonuclease deficiency impairs oligonucleosomal DNA hydrolysis during caspase-dependent cell death: a common trait in human glioblastoma cells. Neuro Oncol. 2016;18(7):950-961.DOI: 10.1093/neuonc/nov315.

Ben-Yehudah A, Aqeilan R, Robashkevich D, Lorberboum-Galski H. Using apoptosis for targeted cancer therapy by a new gonadotropin releasing hormone-DNA fragmentation factor 40 chimeric protein. Clin Cancer Res. 2003;9(3):1179-1190.PMID: 12631624.

Mathew M, Zaineb KC, Verma RS. GM-CSF-DFF40: a novel humanized immunotoxin induces apoptosis in acute myeloid leukemia cells. Apoptosis. 2013;18(7):882-895.DOI: 10.1007/s10495-013-0840-8.

Bagheri F, Safarian S, Eslaminejad MB, Sheibani N. Sensitization of breast cancer cells to doxorubicin via stable cell line generation and overexpression of DFF40. Biochem Cell Biol. 2015;93(6):604-610. DOI: 10.1139/bcb-2015-0007.

Saez NJ, Senff S, Jensen JE, Er SY, Herzig V, Rash LD, et al. Spider-venom peptides as therapeutics. Toxins (Basel). 2010;2(12):2851-2871. DOI: 10.3390/toxins2122851.

Tan L, Bai L, Wang L, He L, Li G, Du W, et al. Antifungal activity of spider venom-derived peptide lycosin-I against Candida tropicalis. Microbiol Res. 2018;216:120-128. DOI: 10.1016/j.micres.2018.08.012.

Liu Z, Deng M, Xiang J, Ma H, Hu W, Zhao Y, et al. A novel spider peptide toxin suppresses tumor growth through dual signaling pathways. Curr Mol Med. 2012;12(10):1350-1360. DOI: 10.2174/156652412803833643.

Shen H, Xie Y, Ye S, He K, Yi L, Cui R. Spider peptide toxin lycosin-I induces apoptosis and inhibits migration of prostate cancer cells. Exp Biol Med (Maywood). 2018;243(8):725-735. DOI: 10.1177/1535370218772802.

Tan H, Huang Y, Xu J, Chen B, Zhang P, Ye Z, et al. Spider toxin peptide lycosin-I functionalized gold nanoparticles for in vivo tumor targeting and therapy. Theranostics. 2017;7(12):3168-3178. DOI: 10.7150/thno.19780.

Amrollahi-Nia R, Akbari V, Shafiee F. DFF40-iRGD, a novel chimeric protein with efficient cytotoxic and apoptotic effects against triple-negative breast cancer cells. Biotechnol Lett. 2021;43(10):1967-1976.DOI: 10.1007/s10529-021-03178-y.

Shafiee F, Rabbani M, Behdani M, Jahanian-Najafabadi A. Expression and purification of truncated diphtheria toxin, DT386, in Escherichia coli: an attempt for production of a new vaccine against diphtheria. Res Pharm Sci. 2016;11(5):428-434. DOI: 10.4103/1735-5362.192496.

Vasina JA, Baneyx F. Expression of aggregation-prone recombinant proteins at low temperatures: a comparative study of the Escherichia coli cspA and tac promoter systems. Protein Expr Purif. 1997;9(2):211-218. DOI: 10.1006/prep.1996.0678.

Feghhi-najafabadi S, Shafiee F. Recombinant production of a mutant form of soluble IL-6 receptor with inhibitory effects against interleukin-6. Iran J Biotechnol.2022;20(1):e3021,98-105.DOI: 10.30498/ijb.2021.278685.3021.

Pourhadi M, Jamalzade F, Jahanian-Najafabadi A, Shafiee F. Expression, purification, and cytotoxic evaluation of IL24-BR2 fusion protein. Res Pharm Sci. 2019;14(4):320-328.

DOI: 10.4103/1735-5362.263556.

Ramírez OT, Zamora R, Espinosa G, Merino E, Bolívar F, Quintero R. Kinetic study of penicillin acylase production by recombinant E. coli in batch cultures. Proccess Biochem. 1994;29(3):197-206. DOI: 10.1016/0032-9592(94)85004-6.

Adelnia R, Shafiee F. Recombinant production and one-step purification of IL-1Ra in Escherichia coli and evaluation of its IL-1 antagonizing efficacy. Iran J Immunol. 2021;18(2):141-149. DOI: 10.22034/iji.2021.89103.1929.

Shafiee F, Minaiyan G, Moazen F, Jahanian-Najafabadi A. Recombinant production and intein-mediated purification of an antimicrobial peptide, BR2. Int J Pept Res Ther. 2017;23:501-507.DOI: 10.1007/s10989-017-9583-7

Sun Z, Chen J, Yao H, Liu L, Wang J, Zhang J, et al. Use of Ssp dnaB derived mini-intein as a fusion partner for production of recombinant human brain natriuretic peptide in Escherichia coli. Protein Expr Purif. 2005;43(1):26-32. DOI: 10.1016/j.pep.2005.05.005.

Humphries HE, Christodoulides M, Heckels JE. Expression of the class 1 outer-membrane protein of Neisseria meningitidis in Escherichia coli and purification using a self-cleavable affinity tag. Protein Expr Purif. 2002;26(2): 243-248.

Aranko AS, Iwaï H. The inducible intein-mediated self-cleaving tag (IIST) system: a novel purification and amidation system for peptides and proteins. Molecules. 2021.;26(19): 5948,1-13. DOI: 10.3390/molecules26195948.

Alishah K, Asad S, Khajeh K, Akbari N. Utilizing intein-mediated protein cleaving for purification of uricase, a multimeric enzyme. Enzyme Microb Technol. 2016;93-94:92-98.DOI: 10.1016/j.enzmictec.2016.08.001.

Minaiyan G, Shafiee F, Akbari V. Survivin Promoter-driven DFF40 gene expression sensitizes melanoma cancer cells to chemotherapy. Int J Toxicol. 2021;40(4):380-387.DOI: 10.1177/10915818211014170.


Refbacks

  • There are currently no refbacks.


Creative Commons LicenseThis work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.